DREAMM: GSK2857916 in Combination for Patients with Relapsed/Refractory Multiple Myeloma
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

DREAMM: GSK2857916 in Combination for Patients with Relapsed/Refractory Multiple Myeloma

Sponsor: GlaxoSmithKline

Protocol GSK207497: A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma.